C., Chan, A., Dubcenco, E., Li, X., TRAVERSE Study Investigators (2023)
Future research is needed to study the use of obesity treatments other than AOM liraglutide and AOM semaglutide, including lifestyle interventions and use of other GLP-1 and non-GLP-1 anti-obesity medications
Wie Kojima und Kangawa, 2005 fuer das gesamte Ghrelin-System darlegen, aktiviert der besetzte Rezeptor die Phospholipase C (PLC), die Inositoltrisphosphat (IP3) freisetzt
There are several different GLP-1 drugs on the market, including: Ozempic (brand name for semaglutide) Wegovy (brand name for semaglutide) Trulicity (brand name for dulaglutide) Victoza (brand name for liraglutide) There are other drugs similar to GLP-1s that aren't in the same exact drug category
Gloire G, Legrand-Poels S, Piette J